However, this marked efficacy was accompanied with increased bile duct proliferation and increased inflammation, cautioning the safety of the combination of FGF19 and PPARα activation in the treatment of obesity and MASLD. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.